1.0 2018-05-07 22:24:34 UTC 2020-05-20 21:04:21 UTC BMDBP00913 Enzyme KNG2 Inorganic ion transport and metabolism (1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting. BMDB0000122 D-Glucose BMDB0004246 Bradykinin 1 >1860 bp ATGAAATTAATCACCATCCTTTTCCTTTGTTCCAGGCTGCTACCAAGTTTAACCCAAGAG TCCTCTCAAGAAATCGACTGCAATGACCAGGATGTATTTAAAGCTGTGGACGCTGCTCTG ACAAAATACAACAGTGAAAACAAGAGTGGCAACCAGTTTGTATTGTACCGCATAACCGAG GTCGCCAGAATGGATAATCCTGACACATTTTATTCCTTGAAGTACCAAATCAAGGAGGGC GACTGTCCTTTTCAAAGTAACAAAACTTGGCAGGACTGTGACTACAAGGACTCTGCACAA GCTGCCACAGGACAGTGCACAGCGACCGTGGCCAAGAGAGGGAATATGAAGTTCTCCGTG GCTATCCAGACCTGCCTGATCACTCCAGCCGAGGGCCCCGTGGTGACAGCCCAGTATGAG TGCCTTGGCTGTGTGCATCCCATATCTACCAAGAGCCCCGACTTGGAGCCTGTTCTGAGA TATGCCATCCAATATTTTAACAACAACACCAGTCATTCCCACCTCTTTGATCTGAAAGAA GTAAAAAGAGCCCAAAAACAGGTGGTGTCTGGATGGAACTATGAAGTTAATTACTCAATT GCACAAACTAATTGTTCCAAGGAGGAATTTTCATTCTTAACTCCAGACTGCAAGTCCCTT TCAAGTGGTGATACTGGTGAATGTACAGATAAAGCACATGTAGATGTCAAGCTAAGAATT TCTTCCTTCTCGCAGAAATGTGACCTTTATCCAGGGGAGGATTTTTTACCCCCCATGGTT TGTGTCGGCTGCCCCAAACCTATACCTGTTGACAGCCCAGACCTGGAGGAAGCTCTGAAC CATTCCATCGCAAAGCTTAATGCAGAGCATGATGGAACCTTCTATTTCAAGATTGACACT GTGAAAAAAGCAACAGTACAGGTGGTAGGTGGATTGAAGTATTCTATTGTGTTCATAGCA AGGGAAACCACATGTTCTAAGGGAAGTAATGAAGAGCTGACCAAGAGTTGTGAGATCAAT ATACATGGTCAAATTCTACACTGTGATGCTAATGTCTATGTGGTGCCTTGGGAGGAAAAA GTTTACCCTACTGTCAACTGTCAACCACTTGGACAGACCTCACTCATGAAAAGGCCTCCG GGTTTTTCACCTTTCCGATCAGTTCAAGTGATGAAAACTGAAGGAAGCACAACTGTAAGT CTACCCCACTCTGCCATGTCACCTGTACAAGATGAAGAGCGGGATTCAGGAAAAGAACAA GGACCCACTCATGGGCATGGCTGGGACCATGGAAAGCAAATAAAATTACATGGCCTTGGC CTTGGCCATAAACATAAGCATGACCAAGGTCATGGGCACCATAGAAGTCATGGTCTTGGC CATGGACATCAAAAGCAACATGGTCTTGGCCATGGACATAAGCATGGTCATGGCCACGGA AAACATAAAAACAAAGGAAAAAACAATGGAAAGCATTATGATTGGAGGACACCCTATTTG GCAAGTTCTTATGAAGATAGCACTACATCCTCTGCACAGACGCAAGAGAAGACAGAAGAG ACAACACTCTCTTCCCTAGCCCAGCCAGGTGTAGCCATTACCTTTCCTGACTTTCAGGAC TCAGATCTCATTGCAACTGTGATGCCTAATACACTACCACCTCACACAGAGAGTGATGAT GACTGGATCCCTGACATCCAGACAGAGCCAAATAGCCTTGCATTTAAATTGATTTCAGAT TTTCCAGAAACAACCTCCCCCAAATGTCCTAGTCGCCCCTGGAAGCCAGTTAATGGAGTG AATCCAACTGTGGAAATGAAAGAGTCTCATGATTTTGATCTTGTTGATGCTCTTCTTTAA 619 68710.0 6.55 1-18 >Kininogen-2 MKLITILFLCSRLLPSLTQESSQEIDCNDQDVFKAVDAALTKYNSENKSGNQFVLYRITE VARMDNPDTFYSLKYQIKEGDCPFQSNKTWQDCDYKDSAQAATGQCTATVAKRGNMKFSV AIQTCLITPAEGPVVTAQYECLGCVHPISTKSPDLEPVLRYAIQYFNNNTSHSHLFDLKE VKRAQKQVVSGWNYEVNYSIAQTNCSKEEFSFLTPDCKSLSSGDTGECTDKAHVDVKLRI SSFSQKCDLYPGEDFLPPMVCVGCPKPIPVDSPDLEEALNHSIAKLNAEHDGTFYFKIDT VKKATVQVVGGLKYSIVFIARETTCSKGSNEELTKSCEINIHGQILHCDANVYVVPWEEK VYPTVNCQPLGQTSLMKRPPGFSPFRSVQVMKTEGSTTVSLPHSAMSPVQDEERDSGKEQ GPTHGHGWDHGKQIKLHGLGLGHKHKHDQGHGHHRSHGLGHGHQKQHGLGHGHKHGHGHG KHKNKGKNNGKHYDWRTPYLASSYEDSTTSSAQTQEKTEETTLSSLAQPGVAITFPDFQD SDLIATVMPNTLPPHTESDDDWIPDIQTEPNSLAFKLISDFPETTSPKCPSRPWKPVNGV NPTVEMKESHDFDLVDALL CAA24736.1 P01045 KNG2_BOVIN V01492 KNG2